Company Interview / Immutep (ASX: IMM) Investor Presentation

CEO Marc Voigt from Immutep (ASX: IMM) highlights the company’s clinical pipeline, focusing on immunotherapy treatments for cancer and autoimmune diseases.

The company’s leading asset, eftilagimod alpha, is now at phase three clinical trial stage in first-line non-small cell lung cancer (NSCLC), in collaboration with Merck (MSD outside the US), combining Immutep’s drug with Keytruda and chemotherapy. Immutep holds over $129 million in cash and a strong patent position, supporting its multi-programme, multi-indication approach.

Beyond oncology, Voigt outlines the IMP761 programme targeting autoimmune diseases, with recent clinical data indicating 80% T-cell inhibition at a 0.9mg/kg dose. Voigt expects further clinical milestones throughout 2025-2027, underpinned by a healthy cash balance and ongoing strategic partnerships.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice that takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD